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Background. This study examined the cellular immunity of 0, 1, 2, and 3 doses of Gardasil vaccine (4vHPV) in girls after 6 years 
and their responses to a subsequent dose of Cervarix vaccine (2vHPV).
Methods. A subset of girls (n = 59) who previously received 0, 1, 2, or 3 doses of 4vHPV 6 years earlier were randomly selected 
from a cohort study of Fijian girls (age 15–19 years). Blood was collected before and 28 days after a dose of 2vHPV. The HPV16- and 
HPV18-specific cellular immune response was determined by IFNγ-ELISPOT and by measurement of cytokines in peripheral blood 
mononuclear cell supernatants.
Results. Six years after 4vHPV vaccination, HPV18-specific responses were significantly lower in the 1- (1D) or 2-dose (2D) 
recipients compared with 3-dose recipients (2D: IFNγ-ELISPOT: P = .008; cytokines, IFNγ: P = .002; IL-2: P = .022; TNFα: P = .016; 
IL-10: P = .018; 1D: IL-2: P = .031; IL-10: P = .014). These differences were no longer significant post-2vHPV. No significant differ-
ences in HPV16 responses (except IL-2, P < .05) were observed between the 2- or 1-dose recipients and 3-dose recipients.
Conclusions. These data suggest that cellular immunity following reduced-dose schedules was detectable after 6 years, although 
the responses were variable between HPV types and dosage groups. The clinical significance of this is unknown. Further studies on 
the impact of reduced dose schedules are needed, particularly in high–disease burden settings.
Keywords. adolescents; cellular immune responses; human papillomavirus vaccine; immune memory; reduced doses.
 
Cervarix (2vHPV) and Gardasil (4vHPV) HPV prophylactic 
vaccines have demonstrated remarkably high vaccine efficacy 
(>96%) against cervical cancer precursors in HPV-naïve indi-
viduals, when administered as standard 3-dose schedules [1–5]. 
The vaccines also induce high levels of type-specific antibody 
that persist for at least 8 and 9  years for 4vHPV and 2vHPV, 
respectively [6, 7].
In 2015, The World Health Organization (WHO) revised 
its recommendation from administering 3 doses of HPV vac-
cine to 2 doses 6  months apart, in girls <15  years old. This 
recommendation was based on clinical studies demonstrating 
non-inferior antibody responses in girls <15  years old who 
received 2 doses and women aged 16–26 years old who received 
3 doses [8, 9]. However, the duration of antibody response fol-
lowing reduced-dose schedules has not been determined, with 
the longest follow up of antibody responses that were not sta-
tistically different between girls who received 1 or 2 doses (0, 
6 month) and those who received 3 doses of 4vHPV and 2vHPV 
being 7 years [10, 11].
The biological basis of vaccination is the generation of 
immune memory characterized by the induction of specific 
memory T and B cell populations. The “help” provided by T 
helper cells are essential for the production of highly-specific 
neutralizing antibodies and immune memory. Cellular immune 
responses (ie, induction of memory B and/or T cells) have been 
reported in individuals vaccinated with 3 doses of either 2vHPV 
or 4vHPV, 1-month after the last vaccine dose, with only 1 study 
documenting cellular responses up to 4  years [8, 9, 12–14]. 
Studies on cellular immune response following reduced-dose 
HPV schedules, particularly over the long-term, are limited. 
We recently published data on the neutralizing antibody (NAb) 
responses to HPV16 and 18 in Fijian girls who were vaccinated 
with 1, 2, or 3 doses of 4vHPV 6  years previously, and their 
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responses to a subsequent dose of 2vHPV [15]. We found that 
6 years following their last dose of 4vHPV, 2-dose recipients had 
similar NAb response as 3-dose recipients. Although lower NAb 
levels were found in 1-dose recipients when compared with 
2- or 3-dose recipients, their levels were at least 5-fold higher 
than unvaccinated girls after 6 years. We also found that post-
2vHPV NAb levels were not statistically different between 1-, 
2-, or 3-dose recipients. Here, we report the HPV-specific cellu-
lar immune responses in terms of IFNγ producing cells as a sur-
rogate for T cell responses, and cytokine production in a subset 
of girls from each dosage groups 6 years following last dose of 
4vHPV, and 1-month after a dose of 2vHPV.
METHODS
Study Design and Participants
Details of the selection criteria and the study procedures includ-
ing the informed consent process were previously described in 
Toh et al. [15]. Briefly, a prospective cohort study was conducted 
in Fiji between February and March 2015. A total of 200 Fijian 
girls (now aged 15–19  years old) who were previously vacci-
nated with 0, 1, 2, or 3 doses of 4vHPV in 2008/9 were recruited. 
Each 4vHPV dosage groups comprised similar numbers of girls 
from the two main ethnic groups: indigenous Fijians (iTaukei) 
and Fijians of Indian Descent (FID). A subset (n = 15/group, 
pre- and postvaccination) of study samples made up of equal 
numbers of iTaukei and FID girls from each dosage group (due 
to our previous study finding ethnic variations in HPV NAb 
responses [15]) were randomly selected for analysis of cellular 
immunity to HPV16 and 18.
Study Procedures
Blood samples were collected on day 0 (6 years following last 
dose of 4vHPV) and 28 days following a single dose of 2vHPV 
(Cervarix, GlaxoSmithKline) to determine immunological 
responses. The blood samples were collected, processed and 
stored accordingly, as previously described in Toh et  al. [15]. 
All laboratory staff were blinded to the vaccination status of 
each participant, and each sample was identified according to 
a unique study number.
Laboratory Procedures
Cryopreserved peripheral blood mononuclear cells (PBMCs) 
were thawed at 37°C, and diluted in R10 media (RPMI 1640, 
supplemented with 10% heat inactivated FBS [Hyclone, Utah, 
USA], and 1% 100x Penicillin/Streptomycin/L-glutamine 
[Gibco, New York, USA]) to 1 ×  106 cells/ mL. PBMCs were 
stimulated with pooled peptides of HPV16 or HPV18 L1 pro-
teins as previously described [14]. The assay controls include 
negative control: DMSO-PBS (diluent for HPV peptides) and 
positive control: PHA (5 μg/mL). PBMCs were stimulated for 
48 h at 37°C and 5% CO2 and were then harvested while super-
natants were collected and stored at –80°C until used for cyto-
kine analyses.
HPV-Specific IFNγ Producing Response
The number of HPV-specific IFNγ producing cells to HPV16 
and HPV18 were measured using an ELISPOT method, accord-
ing to manufacturer’s protocol (BD Bioscience; San Diego, CA). 
The spots were counted using automated EliSpot Reader and 
software version 6.0 (AID GmbH, Strassberg, Germany).
Flow Cytometry
A parallel set of PBMC cultures were set up and stimulated as 
described above to enumerate the memory CD4+ and CD8+ 
populations based on the phenotype CD4+CD45RO+IFNγ+ 
(memory CD4+ T cells) or CD8+CD45RO+IFNγ+ (memory 
CD8+ T cells). Five-six hours before the end of the 48-hour 
incubation, protein inhibitor cocktail (eBioscience Inc, San 
Diego, CA) was added to each culture condition. The cul-
tured PBMCs were then washed and stained with the fol-
lowing markers: CD4-PE, CD8-FITC, CD45RO-APC, and 
IFNγ-BUV737. Unstained PBMCs were used as a control 
and a minimum of 200 000 events per sample were analysed 
using a BD LSRII flow cytometer. Analyses of flow cytom-
etry data were performed using the FlowJo v10.3 software 
(FlowJo LLC, Ashland, OR).
Multiplex-Bead Array Assay
A panel of Th1 (IFNγ, TNFα, IL-2) and Th2 (IL-5 and IL-10) 
cytokines were selected based on previous publications and 
their roles in vaccine response [16–18]. The concentrations of 
IFN-γ, TNF-α, IL-2, IL-10, and IL-5 in the supernatants of the 
PBMC cultures were determined using the Milliplex XMAP kit 
(EMD Millipore, MA) according to manufacturer’s protocol. 
The plate was then read on a Luminex 200 instrument and ana-
lysed using Luminex xPONENT software, version 3.1 (Luminex 
Corporation, TX).
Statistical  Analysis
The primary analysis was the comparison of the number of 
HPV-specific IFNγ producing cells in girls who 6 years earlier 
received 1 or 2 doses of 4vHPV, with girls who received 3 doses 
using the Mann-Whitney U test. Secondary analyses were the 
comparison of the number of HPV-specific IFNγ producing 
cells 1-month after a dose of 2vHPV between the 1- or 2-dose 
group and the 3-dose group using the Mann-Whitney U test, 
and the comparison within each dosage groups were also per-
formed using the Wilcoxon matched-pairs signed rank test. The 
cytokine responses and proportion of HPV-specific T cell pop-
ulations (as determined by flow cytometry; CD4+45RO+IFNγ+ 
or CD8+45RO+IFNγ+) 6 years after the last 4vHPV dose, and 
1-month post-2vHPV between the 1- or 2-dose group and the 
3-dose group were also compared using the Mann-Whitney U 
test. Correlations analyses between the cellular (HPV-specific 
IFNγ producing cells [from ELISPOT] and cytokines) and anti-
body response (previously determined in Toh et al. [15]) were 
performed using the Spearman’s rank test. All statistical analy-
ses were performed using GraphPad Prism 7.0 software. Based 
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on previous published data [14], a sample size of 10 and 16 for 
HPV16 and 18, respectively would provide 60% power to detect 
a 20% difference in number of HPV16/18-specific IFNγ pro-
ducing cells with a 2-sided 5% significance level.
Ethics Approval
The study was conducted according to a protocol approved 
by the Fiji National Research Ethics Review Committee, Fiji 
National Research Committee (2014.5.FNRERC.5.SU), as 
well as the Royal Children’s Hospital Human Research Ethics 
Committee, Melbourne, Australia (34239A). The study was reg-
istered with clinicaltrials.gov, number NCT02276521.
RESULTS
The baseline characteristics of the girls in the whole study 
cohort were previously described in Toh et al. [15]. A subset 
of 59 girls were randomly selected from each dosage group 
(n = 15/group except for 2-dose group, n = 14 [due to limited 
number of samples]) to examine cellular immune responses. 
Each dosage group was made up of approximately equal num-
bers of both ethnic groups (iTaukei and FID). Overall, the 
subset of girls selected for these analyses had similar baseline 
characteristics as the whole study cohort, except that the girls 
in the 3-dose group were older at the time of recruitment, 
and also when the first dose of 4vHPV was given 6 years pre-
viously compared with the girls in the 2- and 1-dose groups 
(Table 1).
HPV-Specific IFNγ-Producing Cell Response Following 1- or 2-Doses of 
4vHPV and Subsequent Responses to a Dose of 2vHPV
Six years after receiving the last dose of 4vHPV (pre-2vHPV), 
the HPV16-specific IFNγ producing cells in the 1- and 
2-dose group were not significantly different from the 3-dose 
group. However, the HPV18-specific IFNγ producing cells 
in the 2-dose (P = .004), but not the 1-dose group were sig-
nificantly lower than the 3-dose group (Figure 1). Following 
Table 1.  Baseline Characteristics
Characteristics
Dosage Groups
P Valuea3 (n = 15) 2 (n = 14) 1 (n = 15) 0 (n = 15)
Age at recruitment, median (IQR), y 18.0 (17.0–18.0) 16.0 (16.0–17.8) 17.0 (17.0–17.5) 18.0 (17.0–19.0) .021
Age at first dose of 4vHPV, median (IQR) 12.0 (11.0–12.0) 9.8 (10.0–11.0) 9.0 (11.0–11.0) NA .001
Time between:
Dose 1 and 2, median (IQR), mo 1.0 (1.0–6.0) 6.0 (1.0–11.0) NA NA .008
Dose 1 and 3, median (IQR), mo 6.0 (6.0–8.0) NA NA NA NA
Time since last dose of 4vHPV, median (IQR), y 5.8 (5.7–5.8) 5.8 (5.4–6.3) 6.3 (6.3–6.3) NA <.0001
Height, median (IQR), cm 162.0 (145.0–168.0) 158.5 (153.8–162.0) 162.0 (154.0–169.0) 161.0 (130.0–170.0) .587
BMI, median (IQR), kg/m2 25.1 (17.3–29.0) 25.4 (21.2–27.1) 23.4 (19.2–25.7) 24.4 (22.1–28.9) .763
Ethnicity, No. (%)
iTaukei 7 (47) 7 (50) 7 (47) 7 (47) 0.997
Fijians of Indian descent 8 (53) 7 (50) 8 (53) 8 (53)
Participant’s education at time of enrollment, 
No. (%)
0.149
No schooling 1 (7) 1 (7) 1 (7) 3 (20)
Secondary school 9 (60) 12 (86) 13 (86) 7 (47)
University 5 (33) 1 (7) 1 (7) 5 (33)
Partner status at enrollment, No. (%)
Boyfriend/married 2 (13) 1 (7) 3 (20) 0 (0) 0.644
No. of children 0 0 0 1 1.000
Consumption of alcohol, No. (%) 0.455
Never consumed 10 (67) 8 (57) 10 (67) 8 (53)
Currently < 1 alcoholic drink per wk 2 (13) 6 (43) 3 (20) 7 (47)
Currently ≥1 alcoholic drinks per wk 3 (20) 0 (0) 2 (13) 0 (0)
Consumption of kava, No. (%) 0.191
Never consumed kava 9 (60) 5 (36) 11 (74) 9 (60)
<1 kava drink per wk 3 (20) 8 (57) 2 (13) 6 (40)
≥1 kava drinks per wk 3 (20) 1 (7) 2 (13) 0 (0)
Cigarette smoking, No. (%)
Smoked ≥100 cigarettes in a lifetime 2 (13) 0 (0) 1 (7) 2 (13) 0.864
Seropositivity to HPV, No. (%)
HPV 16 15 (100) 14 (100) 13 (95) 1 (7)
HPV 18 14 (92) 11 (79) 9 (60) 0 (0)
aThe characteristics of the different dosage groups were compared using the 1-way analysis of variance test for continuous variables or the χ2 test for categorical variables.
Downloaded from https://academic.oup.com/ofid/article-abstract/5/7/ofy147/5040503
by London School of Hygiene & Tropical Medicine user
on 20 July 2018
4 • OFID • Toh et al
a dose of 2vHPV, both HPV16 and 18 IFNγ producing cells 
were not significantly different between the 1- and 2-dose 
group and the 3-dose group. Significantly higher HPV16-
specific IFNγ producing cells were observed compared with 
HPV18-specific IFNγ producing cells pre- and post-2vHPV 
for all dosage groups (P  <  .01). Generally, higher HPV-
specific IFNγ producing cells were observed in FID girls than 
in iTaukei girls for all dosage groups, although most compar-
isons within dosage groups were not significantly different 
(Supplementary Table 1).
Phenotypic Analysis of HPV-Specific IFNγ T-Cell Responses
Flow cytometric analyses were performed to determine the 
proportion of IFNγ-expressing memory T cells in girls who 
received reduced-doses of 4vHPV after 6 years and following 
a dose 2vHPV. The number of samples for this analysis were 
lower than for ELISPOT (n ≥7 depending on dosage groups) 
due to limited number of available cells. Overall, no significant 
differences in HPV16- and 18-specific CD4+CD45RO+IFNγ+ 
cells were observed between all 4vHPV dosage groups pre- and 
post-2vHPV (Supplementary Figure 1). As expected, low lev-
els of CD8+CD45RO+IFNγ++ populations were found across 
all dosage groups, pre- and post-2vHPV (Supplementary 
Figure 2).
Cytokine Responses Following Reduced-Dose 4vHPV Schedules and 
Subsequent Dose of 2vHPV
The cytokine responses 6  years after receiving the last dose 
of 4vHPV and post-2vHPV are summarised in Figure 2. The 
2-dose group had significantly lower IL-2 in response to both 
HPV16 (P = .022) and 18 (P = .013), when compared with the 
3-dose group (Figure 2). In addition, significantly lower IFNγ 
(P = .002), TNFα (P = .016), and IL-10 (P = .018) in response 
to HPV18 were also observed in the 2-dose group, when com-
pared with the 3-dose group. Following 2vHPV, no significant 
differences were observed for any cytokines between the 2- and 
3-dose groups for both HPV types. Table  2 summarises the 
results for all cytokines for the comparison of the 0-, 1-, and 
2-dose groups with the 3-dose-group. Cytokine levels between 
the two ethnic groups were similar across the groups, with only 
a few exceptions (Supplementary Figure 3).
Correlation Analyses of Immune Parameters
We performed correlation analyses to determine the rela-
tionship between cellular and antibody measures (previously 
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Figure 1. Representative ELISPOT well images for the negative and positive controls and human papillomavirus 16 (HPV16) and HPV18 stimulation for each dosage group 
(A). Number of HPV-specific IFNγ-producing cells per 106 peripheral blood mononuclear cells (PBMCs) to HPV16 (B) and HPV18 (C) 6 years after 0, 1, 2, or 3 doses of 4vHPV 
and 1 month after a single booster dose of 2vHPV. PBMCs were stimulated with HPV16 or HPV18 pooled peptides for 2 days, and IFNγ-producing cells were measured by 
ELISPOT. Red bars represent the 3-dose group (n = 15), blue bars represent the 2-dose group (n = 14), purple bars represent the 1-dose group (n = 15), and green bars represent 
the 0-dose group (n = 15). Bars represent mean ± standard error of mean (SEM).
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published in Toh et  al. [15]) of HPV immunity. The num-
ber of HPV-specific 16/18 IFNγ producing cells measured 
by ELISPOT had a moderate correlation with the NAb when 
the dosage groups were pooled (Figure  3). When stratified 
by dosage groups, this is only observed for the 2-dose group 
(Supplementary Figure  4). Although almost all HPV16-
specific cytokines measured showed significant correlations 
with HPV16-specific NAb titres for all 4vHPV dosage groups 
(except for the 1-dose group), only some HPV18-specific 
cytokines in the 2-dose and 0-dose group had moderate sta-
tistically significant correlation with the HPV18-specific NAb 
titres (Supplementary Table  2).  A moderate to strong correl-
ation between the HPV-specific 16/18 cytokines measured and 
the number of HPV-specific 16/18 IFNγ producing cells were 
observed in most cases between the 4vHPV dosage groups pre- 
and post-2vHPV (Supplementary Table 3).
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DISCUSSION
This study examined the cellular immune responses in girls who 
received fewer than 3 doses of 4vHPV 6 years previously and their 
subsequent responses to a single dose of 2vHPV. To our knowl-
edge, this is the first study that has examined cellular immunity 
in girls who received only 1 dose of 4vHPV. Reduced-dose HPV 
schedules, particularly 1-dose schedule is of significant interest 
globally. A single dose of HPV vaccine were found to induce anti-
bodies that last for 7 years (albeit lower levels than 2 or 3 doses) 
and are protective against vaccine type HPV infections [10, 11]. 
Whilst the NAbs are thought to be the mechanism of action for 
HPV vaccine and correlate with protection, the role of cellular 
immunity in long-term protection is poorly understood.
Our study found that although there was no significant dif-
ference in the number of HPV16-specific IFNγ-producing cells 
between the 1- or 2-dose group and 3-dose group after 6 years, 
significantly lower number of IFNγ-producing cells to HPV18 
were observed in the 2-dose group when compared with the 
3-dose group. Interestingly, this was not the case for the 1-dose 
group. Additionally, both 1- and 2-dose groups also had signifi-
cantly lower cytokine (ie, IL-2 and IL-10) levels to HPV18 when 
compared with the 3-dose group. The lower HPV18 responses 
observed in the 2-dose group could be due to a chance find-
ing associated with the small sample size, hence variability in 
responses. This explanation is supported by the fact that the 
number of IFNγ-producing cells in the 3- and 1-dose groups 
in this study were similar to previous studies of CD4+ T cell 
responses 4 years following 4vHPV vaccination [12], and that 
no statistically significant differences in antibody levels were 
observed between the 2 and 3 dose groups in this study [15]. 
A  longitudinal study of this cohort including both antibody 
and cellular immune responses may help to address this find-
ing. Another possible explanation could be due to increased 
priming of cellular immune responses from prior or current 
exposure to HPV18 among girls in the 1-dose group, although 
this is unlikely based on low HPV16/18 prevalent infections 
among pregnant Fijian women who previously received 2 or 1 
dose of 4vHPV 6 years earlier (F. Russell, MBBS, PhD, personal 
communication, 2017). However, it is still possible that prior 
exposure and subsequent clearance of infection may have also 
occurred. These results are consistent with the generally lower 
immune responses induced to HPV18 than to HPV16 observed 
in this study and other previous studies [19–22]. It remains to 
be determined whether these lower cellular immune responses 
(IFNγ-producing cells and cytokine responses) to HPV18 
among girls who received <3 doses of 4vHPV are associated 
with an increased risk of HPV infection, although there are cur-
rently no data that suggest this.
Following a dose of 2vHPV, cellular immunity was not sig-
nificantly different between girls who received 1-, 2-, or 3-doses 
of 4vHPV 6 years previously. This suggests that while the prim-
ing response following reduced-dose 4vHPV may have differed, 
this did not affect the ability to boost cellular immune responses 
following 2vHPV. Larger studies are needed to confirm this 
finding. We also found a moderate correlation between the NAb 
and IFNγ-producing cells for both HPV16 and 18, suggesting a 
possible relationship between these two parameters, and high-
light the role of cellular immune response (IFNγ-producing 
cells) in antibody production. This correlation was less pro-
nounced when the responses were stratified by dosage groups, 
which is likely due to the smaller sample size.
Studies evaluating cellular immune responses following vacci-
nation with HPV prophylactic vaccines (ie, 2vHPV, 4vHPV and 
9vHPV) are limited, particularly in the context of reduced-dose 
HPV schedules. Although NAb are recognised as the primary 
marker of protection against HPV infection, cellular immune 
responses are also likely to have an important role and is sug-
gested to better predict long-term immunity following vaccina-
tion [23]. Einstein et al. compared the immunogenicity induced 
by 3 doses of either 2vHPV or 4vHPV in women aged 18–45 years 
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Figure 3. Correlation between IFNγ-producing cells (from ELISPOT) and neutralizing antibody titers (NAb) specific to human papillomavirus 16 (HPV16) (A) and HPV18 (B), 
regardless of dosage group (n = 59).
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and found higher T cell responses (characterised by the expres-
sion of 2 of these 4 markers on CD4+ cells: CD40L, IFNγ, TNFα, 
IL-2) induced by 2vHPV than 4vHPV to both vaccine (HPV16 
and 18) and nonvaccine HPV types (HPV31 and 45), 1-month 
and at 2 and 4 years following the last vaccine dose [12, 24, 25]. 
The induction of T cell responses to  nonvaccine types in unvac-
cinated individuals has also been demonstrated, suggested to 
be due to shared peptide epitopes between different HPV types 
[26]. Whether this is also true following vaccination is unknown. 
In terms of reduced-dose 4vHPV schedules, Puthanakit et  al. 
found similar HPV-specific CD4+ T-cell responses in girls aged 
9–14  years who received 2 doses of 2vHPV and women aged 
15–25  years who received 3 doses, 1- and 6-month after the 
last dose [27]. However, Smolen et al. found both HPV16 and 
18-specific T cells by IFNγ- ELISPOT assay were lower in girls 
who received 2 doses compared to 3 doses, 1-month after the last 
dose of 4vHPV [14]. Our results extend these findings to 6 years. 
However, it is important to note that the differences in the study 
populations, methodologies and experimental procedures used 
in these studies makes comparison of results difficult.
In contrast to our results by IFNγ-ELISPOT assay, we did not 
observe any significant differences in the proportion of CD4+ 
memory T cells that express IFNγ by flow cytometry. This 
could be due to differences in the specificity and sensitivity of 
the methods. The IFNγ ELISPOT assay measures total IFNγ 
secretion by different immune cell populations and are more 
sensitive in detecting low level responses [28, 29], whereas the 
flow cytometry assay measures intracellular IFNγ production 
by specific immune cells.
The significant increase in Th1 (IFNγ, IL-2 and TNFα) or 
Th2 (IL-10 and IL-5) cytokines measured in this study is con-
sistent with previous studies using either the first generation 
HPV16 VLP vaccine (which did not contain any adjuvant) or 
following 3 doses of 2vHPV [16, 17, 30]. The Th1 cytokines are 
important as they promote antiviral activity and are involved in 
memory responses, whereas the Th2 cytokines promote robust 
antibody responses [18]. Detailed studies that investigate the 
role of different immune cell populations following HPV vac-
cination may elucidate important mechanisms associated with 
protection against HPV infection. It is also important to note 
that the different adjuvants in 4vHPV/9vHPV and 2vHPV may 
contribute to the differences in immunogenicity observed and 
may explain the higher immune responses observed for 2vHPV 
than 4vHPV [31, 32]. It is therefore possible that a difference 
in magnitude of cellular immune response may be found if the 
same vaccine were used for priming and boosting.
There are some limitations in this study. First, the sample size 
for each group is relatively small, particularly for comparison 
of responses between ethnicities, and therefore these results 
should be interpreted with caution. However, the novelty of this 
study represents an important contribution to our knowledge of 
how HPV vaccines induce robust NAb responses. Secondly, the 
lack of a defined HPV epitope for T-cell stimulation assays may 
have underestimated the actual response. Nevertheless, we were 
still able to detect significant differences in cellular immune 
responses using this approach. Thirdly, we did not have any sex-
ual activity data throughout the follow-up period (6 years) to 
correlate with these immune parameters due to ethical consid-
erations of self-swabbing in an otherwise healthy female cohort. 
Further studies incorporating both long-term HPV prevalence 
and immunological data will be critical to help our understand-
ing of the mechanisms of HPV vaccine-induced protection.
In summary, this is the first study of its kind to document 
the elevated cellular immune responses in girls who were pre-
viously vaccinated with at least 1 dose of 4vHPV when com-
pared with unvaccinated girls, 6  years following the last dose 
of 4vHPV, and also following a dose of 2vHPV. Our results 
suggest that reduced-dose 4vHPV schedules may be effect-
ive at inducing long-lasting immune memory, even after only 
1 dose, although larger clinical studies are needed to validate 
these findings. Furthermore, it will be critical to determine 
whether the lower cellular immunity observed for HPV18 fol-
lowing reduced doses of 4vHPV is associated with any increase 
in risk of HPV infection over the long-term, especially in high-
risk populations. These data highlight the continued need for 
rigorous HPV vaccination programmes in settings where there 
remains a high burden of disease.
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